Intercalation-Driven Formation of siRNA Nanogels for Cancer Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34723546.
- Also identified by DOI 10.1021/acs.nanolett.1c03539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RNA interference (RNAi) is a powerful approach in the treatment of various diseases including cancers. The clinical translation of small interfering RNA (siRNA)-based therapy requires safe and efficient delivery vehicles. Here, we report a siRNA nanogels (NG)-based delivery vehicle, which is driven directly by the intercalation between nucleic acid bis-intercalator and siRNA molecules. The intercalation-based siRNA NG exhibits good physiological stability and can enter cells efficiently via different endocytosis pathways. Furthermore, the siRNA NG can not only silence the target genes <i>in vitro</i> but also significantly inhibit the tumor growth <i>in vivo</i>. Therefore, this study provides an intercalation-based strategy for the development of a siRNA delivery platform for cancer therapy. To the best of our knowledge, this is the first report of the intercalation-driven siRNA NG.
Medical subject headings
- Neoplasms